Non-Insulin Therapies For Diabetes Global Market Report 2024

Description

Non-insulin therapies for diabetes are treatments and medications designed to manage blood sugar levels in diabetic patients without the need for insulin injections. These therapies play a crucial role in regulating blood glucose levels for patients who either do not require insulin or prefer alternative methods of treatment.

The primary classes of drugs in the non-insulin therapies for diabetes market include biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. Biguanides, for instance, are oral hypoglycemic agents that target type 2 diabetes by reducing liver glucose production and improving insulin sensitivity. These medications can be administered orally or intramuscularly and are distributed through various channels such as retail pharmacies, hospital pharmacies, and online pharmacies. They are utilized for purposes such as monitoring, diagnosis, treatment, and more.

The non-insulin therapies for diabetes market research report is one of a series of new reports from The Business Research Company that provides non-insulin therapies for diabetes market statistics, including the non-insulin therapies for diabetes industry global market size, regional shares, competitors with non-insulin therapies for diabetes market share, detailed non-insulin therapies for diabetes market segments, market trends, and opportunities, and any further data you may need to thrive in the non-insulin therapies for diabetes industry. These non-insulin therapies for diabetes market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-insulin therapies for diabetes market size has grown strongly in recent years. It will grow from $18.71 billion in 2023 to $19.98 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. Historical growth factors in the non-insulin therapies for diabetes market include the growing prevalence of diabetes, heightened awareness regarding diabetes management, increased healthcare spending, lifestyle changes contributing to higher incidence rates, a rise in diagnoses, government initiatives promoting diabetes care, and greater investment in pharmaceutical research and development.

The non-insulin therapies for diabetes market size is expected to see strong growth in the next few years. It will grow to $26.14 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. Anticipated growth drivers in the forecast period for non-insulin therapies for diabetes comprise the rising prevalence of diabetes, heightened awareness of diabetes management, increased adoption of combination therapies, expansion of the geriatric population, growing healthcare expenditure, the proliferation of telemedicine, and a growing preference for oral medications. Major trends expected in this period include advancements in oral and injectable medications, innovations in drug delivery systems, progress in oral peptide delivery methods, widespread adoption of telemedicine and digital health solutions, and advancements in combination therapies.

The rising prevalence of diabetes is expected to drive the growth of non-insulin therapies in the diabetes market. Diabetes is a chronic condition characterized by elevated blood glucose levels, resulting from insufficient insulin production or improper insulin utilization by the body. Factors contributing to the increasing cases of diabetes include sedentary lifestyles, unhealthy diets, genetic factors, aging populations, obesity, ethnicities, lack of awareness, limited healthcare access, and environmental influences. Non-insulin therapies target diabetes by improving insulin sensitivity, reducing liver glucose production, enhancing glucose uptake in muscle cells, and overall glycemic control. For example, in 2021, the International Diabetes Federation reported that approximately 537 million adults aged 20 to 79 were living with diabetes globally. This number is projected to reach 643 million by 2030 and 783 million by 2045, highlighting the growth trajectory of diabetes cases and the consequent demand for non-insulin therapies.

Leading companies in the non-insulin therapies market are focusing on personalized diabetes management systems to improve patient outcomes through real-time monitoring, data analysis, and customized treatment plans. Personalized systems adapt treatment strategies and monitoring based on individual patient needs, leveraging real-time data and analytics to optimize care. For instance, Eli Lilly and Company introduced the Tempo personalized diabetes management platform in November 2022. This platform integrates the Tempo Smart Button, TempoSmart app, and prefilled insulin pen (Tempo Pen) to deliver tailored guidance for adults with diabetes. The technology assists both type 1 and type 2 diabetes patients and their healthcare providers in making informed, data-driven treatment decisions using Lilly insulins.

In August 2023, Eli Lilly and Company acquired Sigilon Therapeutics Inc. for $309.6 million, enhancing its research and development efforts in encapsulated cell therapies such as SIG-002 for type 1 diabetes treatment. This acquisition reflects Lilly's commitment to advancing solutions that alleviate the continuous disease management burden for individuals with type 1 diabetes. Sigilon Therapeutics Inc. is a biopharmaceutical company specializing in encapsulated cell therapies for type 1 diabetes treatment.

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

North America was the largest region in the non-insulin therapies for diabetes market in 2023. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-insulin therapies for diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-insulin therapies for diabetes market consist of sales of glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, oral medications such as metformin and sulfonylureas, and injectable medications such as glp-1 receptor agonists. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Insulin Therapies For Diabetes Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-insulin therapies for diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-insulin therapies for diabetes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-insulin therapies for diabetes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Biguanides; Sulfonylureas; Thiazolidinedione's; Alpha-Glucosidase Inhibitors; Dipeptidyl peptidase-4 (DPP-4) Inhibitors; Glucagon-like peptide-1 (GLP-1) Analogs; Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral; Intramuscular
3) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
4) By Application: Monitoring; Diagnosis; Treatment; Other Applications
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Sanofi; The Bristol-Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r18937

1. Executive Summary

2. Non-Insulin Therapies For Diabetes Market Characteristics

3. Non-Insulin Therapies For Diabetes Market Trends And Strategies

4. Non-Insulin Therapies For Diabetes Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Non-Insulin Therapies For Diabetes Market Size and Growth

5.1. Global Non-Insulin Therapies For Diabetes Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Non-Insulin Therapies For Diabetes Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Non-Insulin Therapies For Diabetes Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Non-Insulin Therapies For Diabetes Market Segmentation

6.1. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Biguanides
Sulfonylureas
Thiazolidinedione's
Alpha-Glucosidase Inhibitors
Dipeptidyl peptidase-4 (DPP-4) Inhibitors
Glucagon-like peptide-1 (GLP-1) Analogs
Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
6.2. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Intramuscular
6.3. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
6.4. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Monitoring
Diagnosis
Treatment
Other Applications

7. Non-Insulin Therapies For Diabetes Market Regional And Country Analysis

7.1. Global Non-Insulin Therapies For Diabetes Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Non-Insulin Therapies For Diabetes Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Non-Insulin Therapies For Diabetes Market

8.1. Asia-Pacific Non-Insulin Therapies For Diabetes Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Non-Insulin Therapies For Diabetes Market

9.1. China Non-Insulin Therapies For Diabetes Market Overview
9.2. China Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Non-Insulin Therapies For Diabetes Market

10.1. India Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Non-Insulin Therapies For Diabetes Market

11.1. Japan Non-Insulin Therapies For Diabetes Market Overview
11.2. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Non-Insulin Therapies For Diabetes Market

12.1. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Non-Insulin Therapies For Diabetes Market

13.1. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Non-Insulin Therapies For Diabetes Market

14.1. South Korea Non-Insulin Therapies For Diabetes Market Overview
14.2. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Non-Insulin Therapies For Diabetes Market

15.1. Western Europe Non-Insulin Therapies For Diabetes Market Overview
15.2. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Non-Insulin Therapies For Diabetes Market

16.1. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Non-Insulin Therapies For Diabetes Market

17.1. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Non-Insulin Therapies For Diabetes Market

18.1. France Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Non-Insulin Therapies For Diabetes Market

19.1. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Non-Insulin Therapies For Diabetes Market

20.1. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Non-Insulin Therapies For Diabetes Market

21.1. Eastern Europe Non-Insulin Therapies For Diabetes Market Overview
21.2. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Non-Insulin Therapies For Diabetes Market

22.1. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Non-Insulin Therapies For Diabetes Market

23.1. North America Non-Insulin Therapies For Diabetes Market Overview
23.2. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Non-Insulin Therapies For Diabetes Market

24.1. USA Non-Insulin Therapies For Diabetes Market Overview
24.2. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Non-Insulin Therapies For Diabetes Market

25.1. Canada Non-Insulin Therapies For Diabetes Market Overview
25.2. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Non-Insulin Therapies For Diabetes Market

26.1. South America Non-Insulin Therapies For Diabetes Market Overview
26.2. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Non-Insulin Therapies For Diabetes Market

27.1. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Non-Insulin Therapies For Diabetes Market

28.1. Middle East Non-Insulin Therapies For Diabetes Market Overview
28.2. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Non-Insulin Therapies For Diabetes Market

29.1. Africa Non-Insulin Therapies For Diabetes Market Overview
29.2. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Non-Insulin Therapies For Diabetes Market Competitive Landscape And Company Profiles

30.1. Non-Insulin Therapies For Diabetes Market Competitive Landscape
30.2. Non-Insulin Therapies For Diabetes Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Sanofi
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. The Bristol-Myers Squibb Company
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Non-Insulin Therapies For Diabetes Market Other Major And Innovative Companies

31.1. AstraZeneca plc
31.2. Novartis AG
31.3. GSK plc
31.4. Takeda Pharmaceutical Company Limited
31.5. Eli Lilly and Company
31.6. Novo Nordisk A/S
31.7. Boehringer Ingelheim International GmbH
31.8. Les Servier Laboratories
31.9. Sumitomo Dainippon Pharma Co. Ltd.
31.10. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
31.11. Uni-Bio Science Group Ltd.
31.12. Intarcia Therapeutics
31.13. Janssen Pharmaceuticals
31.14. Boan Biotech
31.15. SatRx LLC

32. Global Non-Insulin Therapies For Diabetes Market Competitive Benchmarking

33. Global Non-Insulin Therapies For Diabetes Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Non-Insulin Therapies For Diabetes Market

35. Non-Insulin Therapies For Diabetes Market Future Outlook and Potential Analysis

35.1 Non-Insulin Therapies For Diabetes Market In 2028 - Countries Offering Most New Opportunities
35.2 Non-Insulin Therapies For Diabetes Market In 2028 - Segments Offering Most New Opportunities
35.3 Non-Insulin Therapies For Diabetes Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer